{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T09:56:43Z","timestamp":1764842203445},"reference-count":25,"publisher":"EDP Sciences","issue":"3-4","license":[{"start":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T00:00:00Z","timestamp":1554940800000},"content-version":"vor","delay-in-days":465,"URL":"https:\/\/www.edpsciences.org\/en\/authors\/copyright-and-licensing"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biologie Aujourd'hui"],"published-print":{"date-parts":[[2018]]},"abstract":"<jats:p>Le traitement des cancers par immunoth\u00e9rapie est bas\u00e9 sur l\u2019activation du syst\u00e8me immunitaire de l\u2019h\u00f4te afin d\u2019induire une activit\u00e9 antitumorale. Le traitement par le BCG en instillation endov\u00e9sicale, d\u00e9crit en 1976, fait partie de l\u2019arsenal th\u00e9rapeutique des tumeurs de vessie n\u2019infiltrant pas le muscle (TVNIM) dans les recommandations des soci\u00e9t\u00e9s savantes. Les anticorps monoclonaux dirig\u00e9s contre des inhibiteurs de<jats:italic>checkpoint<\/jats:italic>ont ouvert le champ des traitements possibles en oncologie et ont \u00e9t\u00e9 largement \u00e9tudi\u00e9s depuis 2011, en urologie notamment. L\u2019av\u00e8nement des immunoth\u00e9rapies syst\u00e9miques seules ou en combinaison avec le BCG intra-v\u00e9sical est d\u00e9j\u00e0 en cours d\u2019exploration dans des essais th\u00e9rapeutiques de phase 2 et 3 dans le cancer localis\u00e9, infiltrant le muscle et m\u00e9tastatique.<\/jats:p>","DOI":"10.1051\/jbio\/2018028","type":"journal-article","created":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T08:08:42Z","timestamp":1554970122000},"page":"81-84","source":"Crossref","is-referenced-by-count":5,"title":["Immunoth\u00e9rapie et cancer de la vessie\u2009: \u00e9tat des connaissances actuelles et perspectives futures"],"prefix":"10.1051","volume":"212","author":[{"given":"Louis","family":"Lenfant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"250","published-online":{"date-parts":[[2019,4,11]]},"reference":[{"key":"R1","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol,"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Balar, A.V., Galsky, M.D., Rosenberg, J.E., Powles, T., Petrylak, D.P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J.L., Dawson, N.A., van der Heijden, M.S., Dreicer, R., Srinivas, S., Retz, M.M., Joseph, R.W., Drakaki, A., Vaishampayan, U.N., Sridhar, S.S., Quinn, D.I., Dur\u00e1n, I., Shaffer, D.R., Eigl, B.J., Grivas, PD., Yu, EY., Li, S., Kadel, E.E. 3rd, Boyd, Z., Bourgon, R., Hegde, P.S., Mariathasan, S., Th\u00e5str\u00f6m, A., Abidoye, O.O., Fine, G.D., Bajorin, D.F. (2017b). Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial. Lancet, 389, 67-76.","DOI":"10.1016\/S0140-6736(16)32455-2"},{"key":"R3","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"R4","first-page":"1481","volume":"24","author":"Calmette","year":"1931","journal-title":"Proc R Soc Med"},{"key":"R5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.eururo.2015.02.032","volume":"68","author":"Carosella","year":"2015","journal-title":"Eur Urol"},{"key":"R6","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1464-410X.1994.tb07548.x","volume":"73","author":"Fellows","year":"1994","journal-title":"Br J Urol"},{"key":"R7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.juro.2007.08.122","volume":"179","author":"Herr","year":"2008","journal-title":"J Urol"},{"key":"R8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4103\/0974-7796.106873","volume":"5","author":"Inamoto","year":"2013","journal-title":"Urol Ann"},{"key":"R9","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI114434","volume":"85","author":"Kavoussi","year":"1990","journal-title":"J Clin Invest"},{"key":"R10","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0094-0143(21)00424-9","volume":"19","author":"Lamm","year":"1992","journal-title":"Urol Clin North Am"},{"key":"R11","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"R12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"key":"R13","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"R14","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.lpm.2012.10.017","volume":"42","author":"Neuzillet","year":"2013","journal-title":"Presse Med"},{"key":"R15","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol,"},{"key":"R16","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(17)30007-4","volume":"18","author":"Plimack","year":"2017","journal-title":"Lancet Oncol"},{"key":"R17","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.eururo.2014.02.061","volume":"66","author":"Rentsch","year":"2014","journal-title":"Eur Urol"},{"key":"R18","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.tube.2008.12.001","volume":"89","author":"Rodriguez-Alvarez","year":"2009","journal-title":"Tuberculosis (Edinb)"},{"key":"R19","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.purol.2012.05.002","volume":"22","author":"Roupr\u00eat","year":"2012","journal-title":"Prog Urol"},{"key":"R20","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.purol.2018.07.283","volume":"28","author":"Roupr\u00eat","year":"2018","journal-title":"Prog Urol"},{"key":"R21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.juro.2013.01.084","volume":"190","author":"Sengiku","year":"2013","journal-title":"J Urol"},{"key":"R22","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol,"},{"key":"R23","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol,"},{"key":"R24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.canep.2012.10.010","volume":"37","author":"Uhry","year":"2013","journal-title":"Cancer Epidemiol"},{"key":"R25","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0022-5347(01)67606-7","volume":"153","author":"Vegt","year":"1995","journal-title":"J Urol,"}],"container-title":["Biologie Aujourd'hui"],"original-title":[],"link":[{"URL":"https:\/\/www.biologie-journal.org\/10.1051\/jbio\/2018028\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T18:54:11Z","timestamp":1663268051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.biologie-journal.org\/10.1051\/jbio\/2018028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":25,"journal-issue":{"issue":"3-4"},"alternative-id":["jbio180028"],"URL":"https:\/\/doi.org\/10.1051\/jbio\/2018028","relation":{},"ISSN":["2105-0678","2105-0686"],"issn-type":[{"value":"2105-0678","type":"print"},{"value":"2105-0686","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}